Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  SS&C Technologies Holdings, Inc.    SSNC

SS&C TECHNOLOGIES HOLDINGS, INC.

(SSNC)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

SS&C Technologies : Three reasons why the new real-time benefit rule is good news

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2019 | 04:23pm EDT

On May 16, in an effort to help participants save on the cost of prescriptions, achieve price transparency at the point of care, and improve overall cost-effectiveness, the Centers for Medicare and Medicaid Services (CMS) announced that all Part D plan sponsors are required to implement at least one electronic Real Time Benefit Tool (RTBT) of their choosing by January 1, 2021.1

At SS&C Health we have a unique point of view on what this announcement means for stakeholders across the healthcare continuum. We were early entrants to the Real-Time Benefit (RTB) market. We developed, implemented, and then improved upon some of the first-ever versions of this tool, and we have seen how equipping prescribers with accurate comprehensive patient-centric formulary, benefit, channel and therapeutic alternative information can reduce out-of-pocket costs for patients and drug spend for plans. We believe that the new RTB requirement will support value across the industry and can contribute to better clinical and financial outcomes. Here are three reasons why:

RTB equips providers and patients to make better prescription decisions

RTB is among the most effective tool available for supporting out-of-pocket price transparency, which is especially important in today's consumer-driven environment. The current generation of RTB solutions equips providers with access to patient-specific formulary and benefit information as well as channel options, drug interactions, and therapeutic alternatives so they can work with their patients to prescribe the most affordable, effective, hassle-free medication. This is a big step in the right direction for price-conscious consumers and for pharmacies, providers, and health plans who want to deliver an excellent member experience and promote adherence.

RTB supports better quality ratings

RTB can help improve core performance indicators that affect quality ratings such as patient satisfaction, patient engagement by physicians, and retention of physicians and members.2 When the member's health journey does not get delayed or hard-stopped due to prior authorizations, step therapy, or cost concerns, they have a more positive experience, and that supports higher quality ratings.

RTB amplifies your value-based care efforts

RTB aligns well with Value-Based Care concepts because it gives providers and patients more control over a leading cause of medication nonadherence: cost3. When out-of-pocket costs are lower, we see better adherence, which leads to better financial and clinical outcomes4. This supports dollars saved for all stakeholders who are involved in value-based contracting.

While its potential as a time-saving, money-saving, satisfaction-driving tool is evident; RTB is still a relatively new solution in the marketplace. However, as Part D plans comply with the new rule, wide-spread adoption will drive even more progress when it comes to data analytics and future capabilities. Commercial plans will also reap the benefits of an accelerated learning curve. As RTB providers amass information and experience related to adherence, provider adoption, and ROI for plans; features and capabilities that are in early development phases today, will be operationalized more quickly.

SS&C Health is the only RTB partner to offer outcomes analysis that allows clients to measure actual RTB-influenced savings in addition to projected savings metrics. We launched the industry's first Real-Time Benefit pilot project in 2012, and we have been working to deliver transparency and value ever since. Today our provider footprint is among the best in the industry with more than 164K physicians using our solution each month. In addition to pricing information, therapeutic alternatives, channel options and patient-specific benefit considerations; we provide a fully adjudicated 'faux claim' at the point of prescribing so that the provider can make truly informed treatment decisions together with the patient.

Part D plans: January 2021 is not far away. Now is the time to get started on your Real-Time Benefit implementation. To learn more about RTB and how to evaluate an RTB partner, download our white paper, Real-Time Benefit: Validating Outcomes and Savings for Health Plans, Providers, and Patients.

Footnotes

1: CMS.gov https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-and-part-d-drug-pricing-final-rule-cms-4180-f

2: https://www.managedhealthcareexecutive.com/pbm/four-reasons-payers-are-investing-real-time-benefit-check/page/0/1

3 https://www.ama-assn.org/delivering-care/patient-support-advocacy/8-reasons-patients-dont-take-their-medications

4 https://www.ajmc.com/journals/issue/2016/2016-vol22-n9/cost-benefit-of-appointment-based-medication-synchronization-in-community-pharmacies


Healthcare

Medication adherence , Drug Price Transparency , real-time benefit , consumer drug price transparency , CMS RTB rule

Disclaimer

SS&C Technologies Holdings Inc. published this content on 21 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 21 May 2019 20:22:05 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SS&C TECHNOLOGIES HOLDINGS
09:01aSS&C : Intralinks Forecasts Increase in Global M&A Activity in Second Half of 20..
PR
01:52aSS&C TECHNOLOGIES : HEDIS® 2020—managing high-risk opioid use
PU
08/19ESG INVESTING : trends and challenges
PU
08/16SS&C : Announces Quarterly Dividend
PR
08/16SS&C TECHNOLOGIES : Winners chosen for SS&C's Global Intern Hackathon 2019
PU
08/15SS&C : Announces New Sales Leadership Appointments
PR
08/15PRODUCT TRENDS : what the future holds
PU
08/14SS&C TECHNOLOGIES : Aberdeen Standard Investments Successfully Integrates and Ex..
PR
08/14SS&C TECHNOLOGIES : Potential models for a global transfer agency
PU
08/13SS&C GLOBEOP HEDGE FUND PERFORMANCE : July performance 0.42%; Capital Movement ..
PR
More news
Financials (USD)
Sales 2019 4 600 M
EBIT 2019 1 691 M
Net income 2019 410 M
Debt 2019 7 253 M
Yield 2019 0,88%
P/E ratio 2019 30,2x
P/E ratio 2020 25,5x
EV / Sales2019 4,09x
EV / Sales2020 3,76x
Capitalization 11 566 M
Chart SS&C TECHNOLOGIES HOLDINGS, INC.
Duration : Period :
SS&C Technologies Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SS&C TECHNOLOGIES HOLDINGS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 64,15  $
Last Close Price 45,58  $
Spread / Highest target 55,8%
Spread / Average Target 40,8%
Spread / Lowest Target 29,4%
EPS Revisions
Managers
NameTitle
William Charles Stone Chairman & Chief Executive Officer
Rahul Kanwar President & Chief Operating Officer
Patrick John Louis Pedonti Chief Financial Officer & Senior Vice President
C. V. Channagiri Chief Information Officer
Anthony Caiafa Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SS&C TECHNOLOGIES HOLDINGS, INC.1.04%11 472
MICROSOFT CORPORATION36.27%1 056 817
ATLASSIAN CORPORATION PLC58.77%34 055
CADENCE DESIGN SYSTEMS, INC.60.07%19 499
SYNOPSYS53.11%19 478
SPLUNK INC19.75%18 856